Thursday, July 24, 2014 Last update: 8:03 PM
FreshNews.com - All Company Technology News Since 1996

ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2014 on May 8, 2014

Companies mentioned in this article: ImmunoCellular Therapeutics, Ltd.

LOS ANGELES, May 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report first quarter 2014 financial results on Thursday, May 8, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.

http://photos.prnewswire.com/prnvar/20140109/AQ43875LOGO


    LIVE CALL:               (877) 853-5636 (toll-free);
                             international dial-in: (631)
                             291-4544; conference code
                             35787411


    WEBCAST:                 Interested parties who wish to
                             listen to the webcast should
                             visit the Investor Relations
                             section of ImmunoCellular's
                             website at www.imuc.com, under
                             the Events and Presentations tab.
                             A replay of the webcast will be
                             available one hour after the
                             conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Contact:

ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com

Logo- http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO

SOURCE ImmunoCellular Therapeutics, Ltd.